Implants and Inserts

Kleiner, Lothar W.; Wright, Jeremy C.

doi:10.1016/b978-0-08-087780-8.00099-1

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following features are most commonly listed as the advantages of IDDS: (1) precise distribution of the drug to the target tissue without bioavailability and first-pass metabolism concerns that allows reduction in the active dosage; (2) minimization of side effects due to lower active substance systemic concentrations and absence of risk of incorrect drug administration; (3) prolonged and dose-controlled delivery of the drug, which makes the therapy independent of patient compliance [ 7 , 8 , 9 ]. Moreover, there are numerous possibilities for the smart IDDS equipped with sensors and feedback-controlled drug release IDDS, i.e., epileptic seizure preventing implants [ 10 ] or insulin pumps with glucose level analyzers [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

et al. 2021

View full text Add to dashboard Cite

Precise delivery of therapeutics to the target structures is essential for treatment efficiency and safety. Drug administration via conventional routes requires overcoming multiple transport barriers to achieve and maintain the local drug concentration and commonly results in unwanted off-target effects. Patients’ compliance with the treatment schedule remains another challenge. Implantable drug delivery systems (IDDSs) provide a way to solve these problems. IDDSs are bioengineering devices surgically placed inside the patient’s tissues to avoid first-pass metabolism and reduce the systemic toxicity of the drug by eluting the therapeutic payload in the vicinity of the target tissues. IDDSs present an impressive example of successful translation of the research and engineering findings to the patient’s bedside. It is envisaged that the IDDS technologies will grow exponentially in the coming years. However, to pave the way for this progress, it is essential to learn lessons from the past and present of IDDSs clinical applications. The efficiency and safety of the drug-eluting implants depend on the interactions between the device and the hosting tissues. In this review, we address this need and analyze the clinical landscape of the FDA-approved IDDSs applications in the context of the foreign body reaction, a key aspect of implant–tissue integration.

show abstract

Section: Introductionmentioning

confidence: 99%

“…It is considered that the first applications of IDDSs were subcutaneous implantations of hormone-containing pellets in cattle and poultry in the 1930s [ 8 , 12 ]. Bishop reported the first clinical use of IDDS for hormonal therapy in women [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

et al. 2021

View full text Add to dashboard Cite

show abstract

Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems

Huanbutta,

Puri,

Sharma

et al. 2024

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Pulsatile Chemotherapeutic Delivery Profiles Using Magnetically Responsive Hydrogels

Emi

Barnes

Orton

et al. 2018

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Pulsatile chemotherapeutic delivery profiles may provide a number advantages by maximizing the anticancer toxicity of chemotherapeutics, reducing off-target side effects, and combating adaptive resistance. While these temporally dynamic deliveries have shown some promise, they have yet to be clinically deployed from implantable hydrogels, whose localized deliveries could further enhance therapeutic outcomes. Here, several pulsatile chemotherapeutic delivery profiles were tested on melanoma cell survival in vitro and compared to constant (flatline) delivery profiles of the same integrated dose. Results indicated that pulsatile delivery profiles were more efficient at killing melanoma cells than flatline deliveries. Furthermore, results suggested that parameters like the duration of drug “on” periods (pulse width), delivery rates during those periods (pulse heights), and the number/frequency of pulses could be used to optimize delivery profiles. Optimization of pulsatile profiles at tumor sites in vivo would require hydrogel materials capable of producing a wide variety of pulsatile profiles (e.g., of different pulse heights, pulse widths, and pulse numbers). This work goes on to demonstrate that magnetically responsive, biphasic ferrogels are capable of producing pulsatile mitoxantrone delivery profiles similar to those tested in vitro. Pulse parameters such as the timing and rate of delivery during “on” periods could be remotely regulated through the use of simple, hand-held magnets. The timing of pulses was controlled simply by deciding when and for how long to magnetically stimulate. The rate of release during pulse “on” periods was a function of the magnetic stimulation frequency. These findings add to the growing evidence that pulsatile chemotherapeutic delivery profiles may be therapeutically beneficial and suggest that magnetically responsive hydrogels could provide useful tools for optimizing and clinically deploying pulsatile chemotherapeutic delivery profiles.

show abstract

Implants and Inserts

Cited by 4 publications

References 36 publications

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems

Pulsatile Chemotherapeutic Delivery Profiles Using Magnetically Responsive Hydrogels

Contact Info

Product

Resources

About